Business Description
Welgene Biotech Co Ltd
ISIN : TW0006661002
Share Class Description:
ROCO:6661: Ordinary SharesDescription
Welgene Biotech Co Ltd is engaged in providing clinical testing service. It service and products offerings include next-generation sequencing service, microarray service, OPS diagnostics products, and Biovesicle products. The company also offers clinical testing agents and instruments.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.17 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.53 | |||||
| Debt-to-EBITDA | 7.29 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.34 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -14.3 | |||||
| 3-Year EBITDA Growth Rate | -24.7 | |||||
| 3-Year Book Growth Rate | 0.9 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.55 | |||||
| 9-Day RSI | 39.61 | |||||
| 14-Day RSI | 40.32 | |||||
| 6-1 Month Momentum % | 25 | |||||
| 12-1 Month Momentum % | 23.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.36 | |||||
| Quick Ratio | 1.88 | |||||
| Cash Ratio | 1.41 | |||||
| Days Inventory | 107.26 | |||||
| Days Sales Outstanding | 57.03 | |||||
| Days Payable | 35.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | -48.7 | |||||
| 3-Year Average Share Buyback Ratio | -4 | |||||
| Shareholder Yield % | -13.82 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.31 | |||||
| Operating Margin % | -3.36 | |||||
| Net Margin % | -3.29 | |||||
| FCF Margin % | -7.21 | |||||
| ROE % | -3.36 | |||||
| ROA % | -1.87 | |||||
| ROIC % | -3.09 | |||||
| 3-Year ROIIC % | -18.28 | |||||
| ROC (Joel Greenblatt) % | -3.6 | |||||
| ROCE % | -1.92 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 20.19 | |||||
| PS Ratio | 1.9 | |||||
| PB Ratio | 1.98 | |||||
| Price-to-Tangible-Book | 1.97 | |||||
| Price-to-Operating-Cash-Flow | 892.59 | |||||
| EV-to-EBIT | -67.97 | |||||
| EV-to-EBITDA | 25.7 | |||||
| EV-to-Revenue | 1.8 | |||||
| EV-to-FCF | -25.01 | |||||
| Price-to-Projected-FCF | 2.44 | |||||
| Price-to-Net-Current-Asset-Value | 9.76 | |||||
| Earnings Yield (Greenblatt) % | -1.47 | |||||
| FCF Yield % | -3.83 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers